Description

Efinopegdutide (CAS 2055640-93-0) is a synthetic peptide dual agonist specifically designed to activate both glucagon-like peptide-1 (GLP-1) receptors and glucagon receptors (GluR) with high potency. By simultaneously targeting these two receptors, Efinopegdutide exerts complementary effects on glucose homeostasis, lipid metabolism, and energy expenditure.

The peptide functions as a balanced dual agonist, with strong selectivity and affinity for GLP-1R and GluR, enabling it to modulate insulin secretion, improve glycemic control, and reduce hepatic steatosis in experimental models. Preclinical studies demonstrate that Efinopegdutide is capable of reducing liver fat accumulation, improving serum lipid profiles, and ameliorating inflammatory pathways associated with nonalcoholic steatohepatitis (NASH).

Efinopegdutide is particularly valuable in translational research exploring metabolic syndrome, obesity-related liver disease, and glucose-lipid interactions in endocrine and hepatology laboratories. Its peptide structure ensures central and peripheral receptor engagement, allowing researchers to study the integrative effects of GLP-1 and glucagon signaling pathways.

Supplied in lyophilized form, Efinopegdutide maintains high purity and stability for laboratory applications. It is manufactured in a GMP-certified facility, ensuring reproducibility and high-quality peptide material suitable for both wholesale and retail research use.

For laboratory research use only. Not intended for human or veterinary administration.

Product Specifications

Mechanism of Action & Research Applications

Efinopegdutide exerts its effects through dual activation of GLP-1 and glucagon receptors, providing both glycemic and metabolic regulation.

Key Mechanisms:

1. GLP-1 Receptor Activation:

   • Stimulates insulin secretion in a glucose-dependent manner.

   • Suppresses glucagon secretion to improve glycemic control.

   • Modulates appetite and energy intake in experimental models.

2. Glucagon Receptor Activation:

   • Enhances hepatic energy expenditure.

   • Promotes lipid metabolism and reduces hepatic steatosis.

   • Supports weight loss in preclinical obesity models.

3. Combined GLP-1/GluR Effects:

   • Balanced dual agonism allows improved glucose control without excessive hypoglycemia.

   • Reduces liver fat accumulation and serum triglycerides in NASH models.

   • Exerts anti-inflammatory and antifibrotic effects in hepatic tissue.

4. Translational Research Applications:

   • Nonalcoholic Steatohepatitis (NASH): Reduce hepatic lipid deposition, improve liver enzyme profiles, and explore antifibrotic pathways.

   • Obesity Studies: Assess body weight, energy intake, and metabolic rate modifications.

   • Glucose-Lipid Metabolism: Study interactions between insulin secretion, hepatic glucose output, and lipid metabolism.

   • Combination Therapy Models: Investigate synergy with other metabolic agents in preclinical research.

Efinopegdutide is also valuable for mechanistic studies investigating hormonal regulation, receptor pharmacology, and integrative endocrine-liver interactions. Its dual agonist property enables exploration of central and peripheral effects, providing insights into receptor crosstalk and potential therapeutic strategies for metabolic diseases.

Side Effects (For Reference in Research Models)

In laboratory studies, Efinopegdutide demonstrates a favorable safety profile, with experimental effects including:

• Altered glucose and insulin levels: Dose-dependent responses must be monitored.

• Reduced hepatic lipid content: May vary depending on dietary or genetic models.

• Changes in appetite and body weight: Observed in CNS-penetrant models.

• Potential gastrointestinal effects: Including slowed or accelerated gastric emptying, relevant in NASH models.

• Peptide stability considerations: Avoid repeated freeze-thaw cycles to maintain reproducibility.

Efinopegdutide is intended strictly for laboratory research. Observed effects are for experimental reference only and are not clinical safety data.

Disclaimer

Efinopegdutide is supplied exclusively for laboratory research purposes. It is not for human or veterinary use, nor as a dietary supplement or therapeutic agent. Laboratory safety and handling protocols should always be followed.

Keywords

• Efinopegdutide

• Efinopegdutide CAS 2055640-93-0

• JNJ-64565111 peptide

• Dual GLP-1/glucagon receptor agonist

• NASH research peptide

• Laboratory metabolic disorder peptide

• GMP peptide supplier Efinopegdutide

• Obesity and hepatic steatosis research

• GLP-1R/GluR agonist peptide

• Preclinical endocrine and metabolic studies